首页> 外文期刊>The annals of pharmacotherapy >Successful Alteplase Bolus Administration for a Presumed Massive Pulmonary Embolism During Cardiopulmonary Resuscitation
【24h】

Successful Alteplase Bolus Administration for a Presumed Massive Pulmonary Embolism During Cardiopulmonary Resuscitation

机译:心肺复苏期间推定的大规模肺栓塞成功实施阿替普酶治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To describe the case of a patient successfully resuscitated with bolus alteplase for a presumed massive pulmonary embolism (PE) with associated cardiac arrest. Case Summary: A 54-year-old man presented to the emergency department for evaluation of syncope following recent open reduction and internal fixation of his ankle. On arrival, his condition rapidly deteriorated and progressed to cardiopulmonary arrest. Because of noncompliance with postoperative thromboprophylaxis, there was high suspicion for PE. Following 40 minutes of advanced cardiac life support, empirical alteplase 50 mg was administered intravenously over 2 minutes with return of spontaneous circulation (ROSC) observed 6 minutes later. The diagnosis of PE using computed tomographic angiography was confirmed after fibrinolytic therapy. Although his hospital course was complicated by a gastrointestinal bleed requiring transfusion, he was discharged neurologically intact. Discussion: Clinical guidelines recommend fibrinolytic therapy for patients with PE and cardiac arrest. Data from retrospective analyses, case series, and case reports suggest that various fibrinolytic regimens may facilitate ROSC and improve neurologically intact survival without an increased risk of fatal hemorrhage. Conclusion: The choice of fibrinolytic therapy should be based on hospital availability, with prompt initiation of treatment and incorporation of an intravenous bolus. A reasonable treatment regimen is alteplase 0.6 mg/kg (maximum of 50 mg) or fixed dose of alteplase 50 mg given over 2 to 15 minutes. Resuscitation should be continued for at least 30 minutes, or until ROSC, after fibrinolytic initiation to allow time for the medication to work.
机译:目的:描述一名成功接受推定阿替普酶治疗的患者的案例,该患者因推定为大规模肺栓塞(PE)并伴有心脏骤停。病例摘要:一名54岁的男子在最近行切开复位术及踝关节内固定后,被送往急诊科评估晕厥。到达后,他的病情迅速恶化并发展为心肺骤停。由于不遵守术后血栓预防措施,因此高度怀疑PE。在提供40分钟的高级心脏生命支持后,在2分钟内静脉给予50 mg的阿替普酶经验性药物,并在6分钟后观察到自发循环(ROSC)的恢复。纤溶治疗后,通过计算机断层血管造影对PE的诊断得到了证实。尽管他的住院过程因需要输血的胃肠道出血而变得复杂,但他的神经功能完好无损。讨论:临床指南建议对PE和心脏骤停的患者进行纤溶治疗。回顾性分析,病例系列和病例报告中的数据表明,各种纤溶方案可以促进ROSC并改善神经学上完整的生存,而不会增加致命性出血的风险。结论:纤溶治疗的选择应基于医院的可用性,并应迅速开始治疗并采用静脉推注。合理的治疗方案是0.6毫克/千克的阿替普酶(最多50毫克)或2到15分钟内给予固定剂量的50毫克阿替普酶。纤溶开始后,复苏应至少持续30分钟,或直至ROSC,以留出时间使药物起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号